IL230693A0 - Use of the i-3859 antibody for the detection and diagnosis of cancer - Google Patents

Use of the i-3859 antibody for the detection and diagnosis of cancer

Info

Publication number
IL230693A0
IL230693A0 IL230693A IL23069314A IL230693A0 IL 230693 A0 IL230693 A0 IL 230693A0 IL 230693 A IL230693 A IL 230693A IL 23069314 A IL23069314 A IL 23069314A IL 230693 A0 IL230693 A0 IL 230693A0
Authority
IL
Israel
Prior art keywords
diagnosis
antibody
cancer
detection
Prior art date
Application number
IL230693A
Other languages
English (en)
Hebrew (he)
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of IL230693A0 publication Critical patent/IL230693A0/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL230693A 2011-07-29 2014-01-28 Use of the i-3859 antibody for the detection and diagnosis of cancer IL230693A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161513345P 2011-07-29 2011-07-29
EP11306000 2011-07-29
PCT/EP2012/064876 WO2013017562A1 (en) 2011-07-29 2012-07-30 Use of the antibody i-3859 for the detection and diagnosis of cancer

Publications (1)

Publication Number Publication Date
IL230693A0 true IL230693A0 (en) 2014-03-31

Family

ID=47628653

Family Applications (1)

Application Number Title Priority Date Filing Date
IL230693A IL230693A0 (en) 2011-07-29 2014-01-28 Use of the i-3859 antibody for the detection and diagnosis of cancer

Country Status (14)

Country Link
US (1) US20140170677A1 (cg-RX-API-DMAC7.html)
EP (1) EP2736926A1 (cg-RX-API-DMAC7.html)
JP (1) JP6138780B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140047127A (cg-RX-API-DMAC7.html)
CN (1) CN103717620A (cg-RX-API-DMAC7.html)
AR (1) AR087363A1 (cg-RX-API-DMAC7.html)
AU (2) AU2012292116A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014001979A2 (cg-RX-API-DMAC7.html)
CA (1) CA2842552A1 (cg-RX-API-DMAC7.html)
IL (1) IL230693A0 (cg-RX-API-DMAC7.html)
MX (1) MX2014001160A (cg-RX-API-DMAC7.html)
RU (1) RU2636032C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013017562A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201400500B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016208776A1 (ja) 2015-06-25 2016-12-29 株式会社国際電気通信基礎技術研究所 多器官連関システムを基盤とした予測装置、及び予測プログラム
ES2837015T3 (es) * 2015-10-23 2021-06-29 Novartis Ag Sistema de derivación de proximidades espaciales entre células
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN114594268A (zh) 2016-03-29 2022-06-07 无限生物制药公司 用以预防或治疗肾脏疾病的活性组分的候选物质的筛选装置和筛选方法
CN109414504B (zh) 2016-03-29 2022-04-08 无限生物制药公司 药物组合物或食品组合物及评价活性成分体内效果的方法
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN116903741A (zh) 2016-06-20 2023-10-20 科马布有限公司 特异性结合于pd-l1的抗体或其抗原结合片段及其用途
JP2021502071A (ja) * 2017-11-07 2021-01-28 エックス４ ファーマシューティカルズ， インコーポレイテッド がんバイオマーカーおよびその使用方法
JP2021521439A (ja) * 2018-04-13 2021-08-26 エックス４ ファーマシューティカルズ， インコーポレイテッド がん血清バイオマーカーおよびその使用方法
CA3171250A1 (en) 2020-03-10 2021-09-16 E. Lynne KELLEY Methods for treating neutropenia

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999050461A1 (en) 1998-03-30 1999-10-07 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
ATE265219T1 (de) 2000-05-09 2004-05-15 Univ British Columbia Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
WO2001094420A1 (en) 2000-06-05 2001-12-13 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
WO2004096839A1 (en) * 2003-05-02 2004-11-11 Polyphor Ag Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity
EP1871807B1 (en) * 2005-02-18 2012-11-28 Dana-Farber Cancer Institute, Inc. Antibodies against cxcr4 and methods of use thereof
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
RS55740B1 (sr) * 2006-10-02 2017-07-31 Squibb & Sons Inc Humana antitela koja se vezuju za cxcr4 i njihove upotrebe
EP2172485A1 (en) * 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
EP2246364A1 (en) 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV

Also Published As

Publication number Publication date
AR087363A1 (es) 2014-03-19
CA2842552A1 (en) 2013-02-07
JP6138780B2 (ja) 2017-05-31
MX2014001160A (es) 2014-07-14
KR20140047127A (ko) 2014-04-21
US20140170677A1 (en) 2014-06-19
RU2014103054A (ru) 2015-09-10
JP2014523920A (ja) 2014-09-18
ZA201400500B (en) 2014-11-26
EP2736926A1 (en) 2014-06-04
AU2017204043A1 (en) 2017-07-06
BR112014001979A2 (pt) 2017-02-21
RU2636032C2 (ru) 2017-11-17
AU2012292116A1 (en) 2014-02-06
WO2013017562A1 (en) 2013-02-07
CN103717620A (zh) 2014-04-09

Similar Documents

Publication Publication Date Title
ZA201202076B (en) Anti-cmet antibody and its use for the detection and the diagnosis of cancer
IL250691B (en) Anti-ox40 antibodies and methods of using them
EP2652506A4 (en) USE OF ANTIBODIES AGAINST CXCL16 AND CXCR6 FOR TREATMENT OR FOR THE DETECTION OF CANCER
ZA201401326B (en) Novel anti-cxcr4 antibody and its use for the detection and diagnosis of cancer
ZA201300519B (en) Novel antibody for the diagnosis and/or prognosis of cancer
IL230693A0 (en) Use of the i-3859 antibody for the detection and diagnosis of cancer
EP2652508A4 (en) USE OF ANTI-CXCL13 ANTI-CXCR5 ANTIBODIES FOR THE TREATMENT OR DETECTION OF CANCER
ZA201408236B (en) Anti-ly6e antibodies and immunoconjugates and methods of use
IL232778A0 (en) Antibodies against 1l–pd and uses thereof
ZA201500457B (en) Anti-kit antibodies and uses thereof
IL238227A0 (en) Antibodies against c16orf54 and uses thereof
ZA201404675B (en) Anti-lrp5 antibodies and methods of use
ZA201409298B (en) In vitro method for the diagnosis and surveillance of cancer
EP2652507A4 (en) CANCER DETECTION BY ANTI-CCL25 ANTI-CCR9 ANTIBODIES
PL2869837T3 (pl) Przeciwciała przeciw teofilinie i sposoby ich stosowania
SG11201402115TA (en) Methods for diagnosis and/or prognosis of gynecological cancer
PT2984108T (pt) Anticorpos anti-s100a7 para o tratamento e diagnóstico de cancro
EP3006942A4 (en) REAGENT WITH ANTI-LGR6 ANTIBODIES FOR THE DETECTION AND DIAGNOSIS OF CANCER
EP2812694A4 (en) TESTS AND METHODS FOR DIAGNOSING OVARIAN CANCER
ZA201309332B (en) Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer